Sentry Investments Corp. Buys Shares of 86,300 Johnson & Johnson (JNJ)

Sentry Investments Corp. bought a new position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 86,300 shares of the company’s stock, valued at approximately $11,417,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. Premier Asset Management LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares during the period. Lbmc Investment Advisors LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares during the period. Halbert Hargrove Russell LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares during the period. Finally, Stratford Consulting LLC increased its stake in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 65.90% of the company’s stock.

JNJ has been the topic of a number of recent analyst reports. Goldman Sachs Group lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, September 1st. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a research note on Monday, October 30th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Finally, UBS restated an “underweight” rating on shares of Johnson & Johnson in a research note on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $144.59.

Shares of Johnson & Johnson (NYSE JNJ) traded up $1.40 during mid-day trading on Wednesday, reaching $141.07. The company had a trading volume of 1,120,404 shares, compared to its average volume of 5,877,685. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The company has a market capitalization of $373,453.13, a P/E ratio of 19.47, a P/E/G ratio of 2.83 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

TRADEMARK VIOLATION WARNING: This news story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/12/06/sentry-investments-corp-buys-shares-of-86300-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply